Stockscreener 앱 받기
37.02
0.59%
-0.22
시장 영업 전:
36.88
-0.14
-0.38%
전일 마감가:
$37.24
열려 있는:
$37.54
하루 거래량:
1.36M
Relative Volume:
0.63
시가총액:
$6.01B
수익:
-
순이익/손실:
$-328.94M
주가수익비율:
-15.12
EPS:
-2.4487
순현금흐름:
$-266.00M
1주 성능:
-7.38%
1개월 성능:
+0.46%
6개월 성능:
+186.09%
1년 성능:
+416.32%
1일 변동 폭
$36.65
$38.20
1주일 범위
$36.40
$40.12
52주 변동 폭
$3.72
$43.73
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
37.02 | 6.04B | 0 | -328.94M | -266.00M | -2.4487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2025-11-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-10-16 | 개시 | Stifel | Hold |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Rafferty Asset Management LLC Purchases 57,139 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences: Trio Of Approvals Beckon For Lead DrugStill Bullish (NASDAQ:COGT) - Seeking Alpha
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility - Yahoo Finance
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity - Yahoo Finance
Cogent Biosciences (COGT) Reveals Promising Results in Latest Be - GuruFocus
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval - Insider Monkey
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Cogent Biosciences Reports Promising 48-Week Results for Bezuclastinib in NonAdvanced Systemic Mastocytosis Patients - Quiver Quantitative
Cogent Biosciences Highlights Additional Data with Six - GlobeNewswire
A Look At Cogent Biosciences (COGT) Valuation After A Strong One Year Shareholder Return - Sahm
Cogent Biosciences, Inc. (COGT) - DirectorsTalk Interviews
Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval - Yahoo Finance
How Do Cogent Biosciences’ Growing Losses and ESOP Shelf Shape Its Capital Strategy Narrative (COGT)? - simplywall.st
COGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk - Sahm
Cogent Biosciences, Inc. $COGT Stock Position Cut by NEOS Investment Management LLC - MarketBeat
Cogent Biosciences, Inc. (COGT) Stock Analysis: Biotechnology Innovator With 40% Upside Potential - DirectorsTalk Interviews
Quarterly Risk: What is Cogent Biosciences Incs 5 year growth outlookMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million - AOL.com
Readystate Asset Management LP Takes $714,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Piper Sandler raises Cogent stock price target on drug launch outlook By Investing.com - Investing.com Australia
Piper Sandler raises Cogent stock price target on drug launch outlook - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
COGT Sees a Boost in Price Target and Maintained Overweight Rati - GuruFocus
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib NDA Filings Earnings Update And New Shelf Registration - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Progress Versus Market Expectations This Quarter - Kalkine Media
(COGT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Cogent Biosciences (COGT) Reports Strong Cash Position by Year-E - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
COGT Plans to Launch Bezuclastinib Following Key Regulatory Subm - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Issues Earnings Results - MarketBeat
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
BRIEF-Cogent Biosciences Q4 Operating Expenses USD 99.493 Million - TradingView
Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences announces proposed concurrent public offerings - MSN
272,460 Shares in Cogent Biosciences, Inc. $COGT Acquired by Principal Financial Group Inc. - MarketBeat
How cyclical is Cogent Biosciences Inc.’s revenue streamEarnings Summary Report & Safe Swing Trade Setups - mfd.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Exploring a Potential 43% Upside with Innovative Biotech Approaches - DirectorsTalk Interviews
What are Cogent Biosciences Inc.’s recent SEC filings showingMarket Performance Report & Risk Controlled Stock Pick Alerts - mfd.ru
Cogent Biosciences, Inc. $COGT Shares Bought by Candriam S.C.A. - MarketBeat
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - Investing News Network
Support Test: Is Cogent Biosciences Inc forming a double bottomWatch List & Short-Term Trading Alerts - baoquankhu1.vn
(COGT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Federated Hermes Inc. Purchases 93,223 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Is FDA Breakthrough Status And Rapid Review For Bezuclastinib Reshaping The Case For Cogent Biosciences (COGT)? - Sahm
Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News - Sahm
Commit To Buy Cogent Biosciences At $25, Earn 17.2% Using Options - Nasdaq
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):